Regeneron Phase 2 COURAGE trial reports muscle-loss prevention
Regeneron said its Phase 2 COURAGE trial found trevogrumab prevented lean mass and muscle loss during GLP-1 receptor agonist-induced weight loss.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.